The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment

Table 2

The background data, including age, body weight, body height, years since menopause, serum levels of calcium, phosphate and renal function indicated by creatinine, and the measured numeric values of the BMD, NTX/Cr, BAP, PTH, and the physical parameters at the baseline.

Baseline	BP	BP + PPI
Number of cases	47	47
Age (years old)	70.1 ± 8.5	68.8 ± 8.5
Body weight (Kg)	50.1 ± 7.8	51.9 ± 7.1
Body height (cm)	150.1 ± 9.5	151.8 ± 8.6
Years since menopause	20.0 ± 14.3	18.2 ± 11.2
Calcium (mg/dL)	9.2 ± 0.5	9.2 ± 0.6
Phosphate (mg/dL)	3.7 ± 0.3	3.6 ± 0.5
Creatinine (mg/dL)	0.6 ± 0.1	0.8 ± 0.8
BMD (mg/cm^3); YAM 181.4 ± 13.1	66.3 ± 36.8	55.5 ± 31.1
NTX/Cr; (nmolBCE/mmol·Cr)	55.8 ± 16.1	63.4 ± 19.3
BAP (U/L)	17.3 ± 6.6	20.7 ± 13.2
PTH (pg/mL)	41.0 ± 10.5	43.0 ± 16.2
Physical functioning	40.4 ± 15.2	33.5 ± 14.5
Bodily pain	41.2 ± 9.4	36.5 ± 9.5

Average ± standard deviation.